HAMBURG, Germany, Nov. 6, 2009 (GLOBE NEWSWIRE) -- Evotec AG (Frankfurt:EVT)
(TecDAX) (Nasdaq:EVTC) will report its financial results for the third quarter
of 2009 on Thursday, 12 November 2009.
The Company is going to hold a conference call to discuss the results and to
give an update on its business strategy:
Conference call details:
Date: Thursday, 12 November 2009
Time: 09.30 a.m. CST
08.30 a.m. GMT
03.30 a.m. US time (East Coast)
From Europe: +49.(0)69.2222 9550 (Germany)
+44.(0)20.7784 1036 (UK)
From the US: +1.718.354 1152
Access Code: 9023741
A simultaneous slide presentation for participants dialing in via phone is
available at www.equitystory.com, password: evotec121109.
Webcast details
To join the audio webcast and to access the presentation slides you will find a
link on our home page www.evotec.com shortly before the event.
A replay of the conference call will be available for 24 hours and can be
accessed in Europe by dialing +49.(0)69.2222 2236 (Germany) or +44.(0)20.7111
1244 (UK) and in the US by +1.347.366 9565. The access code is 9023741#. The
on-demand version of the webcast will be available on our website:
www.evotec.com - Investors - Finance - Financial Reports 2008 - 2009.
About Evotec AG
Evotec is a leader in the discovery and development of novel small molecule
drugs. The Company has built substantial drug discovery expertise and an
industrialized platform that can drive new innovative small molecule compounds
into the clinic. In addition, Evotec has built a deep internal knowledge base in
the treatment of diseases related to neuroscience, pain, and inflammation.
Leveraging these skills and expertise, the Company intends to develop
best-in-class differentiated therapeutics and deliver superior science-driven
discovery alliances with pharmaceutical and biotechnology companies. Evotec has
long-term discovery alliances with partners including Boehringer Ingelheim,
CHDI, Novartis, Ono Pharmaceutical and Roche. Evotec has product candidates in
clinical development and a series of preclinical compounds and development
partnerships, including for example a strategic alliance with Roche for the EVT
100 compound family, subtype selective NMDA receptor antagonists for use in
treatment-resistant depression. For additional information please go to
www.evotec.com.
-0-
CONTACT: Evotec AG
Dr Werner Lanthaler, Chief Executive Officer
+49.(0)40.56081-242
werner.lanthaler@evotec.com
